Immunome, Inc.
IMNM
$19.37
$2.2813.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.44% | 16.74% | -13.76% | -35.50% | -0.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.44% | 16.74% | -13.76% | -35.50% | -0.62% |
| Cost of Revenue | 91.05% | 180.45% | 337.24% | 461.06% | 416.78% |
| Gross Profit | -102.97% | -217.91% | -540.87% | -1,228.42% | -986.04% |
| SG&A Expenses | 37.89% | 60.26% | 65.52% | 67.65% | 101.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.72% | 143.81% | 229.38% | 280.15% | 270.82% |
| Operating Income | -85.17% | -162.70% | -298.52% | -434.17% | -392.89% |
| Income Before Tax | 27.05% | 19.12% | 11.60% | -174.29% | -1,290.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.05% | 19.12% | 11.60% | -174.29% | -1,290.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.05% | 19.12% | 11.60% | -174.29% | -1,290.60% |
| EBIT | -85.17% | -162.70% | -298.52% | -434.17% | -392.89% |
| EBITDA | -85.22% | -163.31% | -298.63% | -437.26% | -396.07% |
| EPS Basic | 51.28% | 45.30% | 41.94% | -55.52% | -235.99% |
| Normalized Basic EPS | -41.05% | -72.46% | -77.41% | -63.35% | 1.06% |
| EPS Diluted | 51.22% | 45.24% | 41.88% | -55.64% | -235.64% |
| Normalized Diluted EPS | -41.05% | -72.46% | -77.41% | -63.35% | 1.06% |
| Average Basic Shares Outstanding | 47.90% | 73.88% | 120.99% | 195.47% | 340.31% |
| Average Diluted Shares Outstanding | 47.90% | 73.88% | 120.99% | 195.47% | 340.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |